CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 28 enrolled
Drug / intervention
Leuprolide +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03298087
NCT03298087Phase 2Completed
CompareCT.gov

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

VA Office of Research and Development·interventional·Posted Sep 29, 2017·Updated Aug 1, 2025

In Brief

A Phase 2 clinical trial evaluating radical prostatectomy, stereotactic body radiotherapy, and 3 other interventions for Newly Diagnosed Oligometastatic Prostate Cancer. Completed, enrolled 28 participants across 3 sites.

Detailed Summary

This is a trial for patients with newly diagnosed metastatic prostate cancer with 5 or fewer sites of metastases. The trial involves surgery (removal of the prostate) or radiation to the prostate, six months of hormone therapy, and stereotactic body radiotherapy to the sites of metastasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNewly Diagnosed Oligometastatic Prostate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 29, 2017
Enrollment StartJul 1, 2018
Primary CompletionMar 31, 2024
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 8.8 years ago

Interventions

radical prostatectomyprocedure

surgical removal of the prostate

stereotactic body radiotherapyradiation

Highly targeted radiation

Leuprolidedrug

Lowers serum testosterone

apalutamidedrug

antiandrogen

abirateronedrug

Inhibits androgen synthesis